
    
      This study is a prospective, one-arm, phase II clinical study to evaluate the safety and
      efficacy of SHR-1210 in combination with trastuzumab plus oxaliplatin and capecitabine for
      HER2-positive locally advanced resectable gastric adenocarcinoma and gastroesophageal
      junction adenocarcinoma during the perioperative treatment.
    
  